本发明提供无定形碳酸钙(ACC)和作为稳定剂的聚磷酸/聚磷酸酯/聚磷酸盐、双膦酸/双膦酸酯/双膦酸盐或其药物盐的固体组合物。所述稳定剂稳定ACC并且持续长时间段防止结晶成结晶碳酸钙(CCC)，即使在含水悬浮液中。本发明还提供包含固体ACC组合物的药物组合物以及所述药物组合物在治疗某些疾病和状况中的用途。

一种固体组合物，包含无定形碳酸钙(ACC)和作为稳定剂的无机聚磷酸/聚磷酸酯/聚磷酸盐或其药学上可接受的盐，其中所述稳定剂的P原子和所述ACC的Ca原子之间的摩尔比(P : Ca摩尔比)是至少约1 : 90，并且其中所述组合物持续至少7天是稳定的。

The present invention provides a solid composition of amorphous calcium carbonate (ACC) and polyphosphate/polyphosphate/polyphosphate, bisphosphonic acid/bisphosphonate/bisphosphonate or a pharmaceutical salt thereof as a stabilizer. The stabilizer stabilizes ACC and persists for long periods of time to prevent crystallization into crystalline calcium carbonate (CCC), even in aqueous suspensions. The invention also provides pharmaceutical compositions comprising solid ACC compositions and the use of said pharmaceutical compositions in the treatment of certain diseases and conditions.

A solid composition comprising amorphous calcium carbonate (ACC) and inorganic polyphosphate/polyphosphate/polyphosphate or a pharmacologically acceptable salt thereof as a stabilizer where the molar ratio (P: Ca molar ratio) between the P atom of the stabilizer and the Ca atom of the ACC is at least approximately 1: 90, and where the composition lasts at least 7 days is stable.